Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: An electronic device is provided for managing assignment of peripheral devices in a virtualization environment. The electronic device can include a user interface configured to display one or more representations of virtual desktops. The virtual desktops are associated with corresponding virtual machines. The electronic devices can also include one or more processors configured to provide to the user interface to display one or more representations of the peripheral devices based on detection that the peripheral devices are communicatively coupled to a control virtual machine of the virtualization environment. The one or more processors can be further configured to detect one or more first inputs received with respect to the one or more representations of the virtual desktops and the one or more representations of the peripheral devices; and facilitate to establish one or more associations between the peripheral devices and the virtual machines.

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: An electronic device is provided for managing assignment of peripheral devices in a virtualization environment. The electronic device can include a user interface configured to display one or more representations of virtual desktops. The virtual desktops are associated with corresponding virtual machines. The electronic devices can also include one or more processors configured to provide to the user interface to display one or more representations of the peripheral devices based on detection that the peripheral devices are communicatively coupled to a control virtual machine of the virtualization environment. The one or more processors can be further configured to detect one or more first inputs received with respect to the one or more representations of the virtual desktops and the one or more representations of the peripheral devices; and facilitate to establish one or more associations between the peripheral devices and the virtual machines.

Abstract: Described herein are kinase inhibitor compounds of Formula IV: wherein Rb, R6, T, Y, and Z are defined herein. Also described herein are methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

Abstract: A multichannel audio format provides a truly discrete as well as a backward compatible mix for surround-sound, front or other discrete audio channels in cinema, home theater, or music environments. The additional discrete audio signals are mixed with the existing discrete audio channels into a predetermined format such as the 5.1 audio format. In addition these additional discrete audio channels are encoded and appended to the predetermined format as extension bits in the bitstream. The existing base of multichannel decoders can be used in combination with a mix decoder to reproduce truly discrete N.1 multichannel audio.

Abstract: The present invention provides a method and apparatus for decoding two-channel matrix encoded audio (32) to reconstruct multichannel audio (34) that more closely approximates a discrete surround-sound presentation. This is accomplished by subband filtering (54) the two-channel matrix encoded audio, mapping (70) each of the subband signals into an expanded sound field (68) to produce multichannel subband signals, and synthesizing (78) those subband signals to reconstruct multichannel audio. By steering the subbands separately about an expanded sound field, various sounds can be simultaneously positioned about the sound field at different points allowing for more accurate placement and more distinct definition of each sound element.

Abstract: A listener can experience the sound of virtual loudspeakers over headphones with a level of realism that is difficult to distinguish from the real loudspeaker experience. Sets of personalized room impulse responses (PRIRs) are acquired for the loudspeaker sound sources over a limited number of listener head positions. The PRIRs are then used to transform an audio signal for the loudspeakers into a virtualized output for the headphones. Basing the transformation on the listener's head position, the system can adjust the transformation so that the virtual loudspeakers appear not to move as the listener moves the head.

Abstract: A multi-channel audio compression technology is presented that extends the range of sampling frequencies compared to existing technologies and/or lowers the noise floor while remaining compatible with those earlier generation technologies. The high-sampling frequency multi-channel audio is decomposed into core audio up to the existing sampling frequencies and a difference signal up to the sampling frequencies of the next generation technologies. The core audio is encoded using a first generation technology such as DTS, Dolby AC-3 or MPEG I or II such that the encoded core bit stream is fully compatible with a comparable decoder in the market. The difference signal is encoded using technologies that extend the sampling frequency and/or improve the quality of the core audio. The compressed difference signal is attached as an extension to the core bit stream. The extension data will be ignored by the first generation decoders but can be decoded by the second generation decoders.